# A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)

> **NCT03951753** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 117 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Semaglutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03951753
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-28
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-08
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03951753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03951753, "A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03951753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*